Aripiprazole in autism spectrum disorders and fragile X syndrome.

Aripiprazole in autism spectrum disorders and fragile X syndrome.
复制标题

DOI:
10.1016/j.nurt.2010.04.001
复制
发表时间:
2010-07
期刊:
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
影响因子:
--
通讯作者:
McDougle CJ
McDougle CJ
中科院分区:
其他
文献类型:
--
作者:
Erickson CA;Stigler KA;Posey DJ;McDougle CJ

文献摘要

参考文献

被引文献

相似文献

自闭症谱系障碍(ASD)是以社会技能障碍、重复行为为特征的儿童期发育性障碍,对于典型的自闭症障碍来说,是一种严重的沟通障碍。除了这些核心症状,自闭症患者经常表现出干扰性的行为症状,包括以攻击性为标志的易怒、自残行为(SIB)和严重的脾气暴躁。阿立哌唑是一种非典型或新一代抗精神病药物,具有影响多巴胺能和5-羟色胺能神经传递的独特作用机制。这种药物已经被发现在几个适应症上有效,包括最近用于治疗与青少年自闭症相关的过敏性疾病。脆性X综合征(FXS)是导致发育障碍的最常见的遗传性原因,也是导致自闭症的最常见的单基因原因。与特发性自闭症一样,患有FXS的人经常表现出易怒行为。然而,到目前为止,对这种疾病的研究还没有集中在这一目标症状群上。初步的初步研究已经开始评估阿立哌唑对患有FXS的青年易激性的影响。
Autism spectrum disorders (ASDs) are childhood onset developmental disorders characterized by social skills impairment, repetitive behavior, and for classic autistic disorder, a significant communication impairment. In addition to these core symptom domains, persons with ASDs frequently exhibit interfering behavioral symptoms, including irritability marked by aggression, self-injurious behavior (SIB), and severe tantrums. Aripiprazole is an atypical or newer generation antipsychotic with a unique mechanism of action impacting dopaminergic and serotonergic neurotransmission. The drug has been found efficacious for several indications, including most recently for use targeting irritability associated with autistic disorder in youth. Fragile X Syndrome (FXS) is the most common inherited cause of developmental disability and most common known single gene cause of ASDs. As in idiopathic ASDs, irritable behavior is often exhibited by persons with FXS. Research to date in this disorder, however, has not focused on this target symptom cluster. Initial pilot study has begun to assess the impact of aripiprazole on irritability in youth with FXS.
DOI: 10.2165/00023210-200923060-00005
发表时间: 2009-01-01
期刊: CNS DRUGS
影响因子: 6
作者:
Masi, Gabriele;Cosenza, Angela;Salvadori, Francesco
通讯作者: Salvadori, Francesco
DOI: 10.1002/ajmg.b.30241
发表时间: 2005-11-05
影响因子: 2.8
作者:
Hessl, D;Tassone, F;Hagerman, RJ
通讯作者: Hagerman, RJ
DOI: 10.1016/s0014-2999(02)01532-7
发表时间: 2002-04-26
影响因子: 5
作者:
Jordan, S;Koprivica, V;Altar, CA
通讯作者: Altar, CA
DOI: 10.1007/s00213-002-1344-3
发表时间: 2003-04-01
期刊: PSYCHOPHARMACOLOGY
影响因子: 3.4
作者:
Casey, DE;Carson, WH;Ingenito, GG
通讯作者: Ingenito, GG
DOI: 10.3928/0090-4481-20070901-09
发表时间: 2007-09-01
期刊: PEDIATRIC ANNALS
影响因子: 1.1
作者:
Erickson, Craig A.;Posey, David J.;McDougle, ChristopherJ.
通讯作者: McDougle, ChristopherJ.